The clinical wound unit of the Hospital Universitari de la Santa Creu de Vic (HUSC), clinical partner of TR2Lab, advances in the application of biological therapies for wound care by launching a new Good Manufacturing Practice (GMP) facility.

The new outpatient area of ​​the HUSC includes a new GMP facility that will allow to increase the security and the results of the autologous growth factor therapy that is currently used at the hospital. In addition, this new equipment will facilitate the application of new therapies, and the development of research focus on advanced new therapies with biological products, cells, and tissues.

This equipment is available throughout the regional institutions for advancing in new therapeutic strategies and research projects. This is a great opportunity for TR2Lab’s membres which will collaborate with this new infrastructure in the development of research projects for which it has recently received research fundings from Spanish and European institutions (FIS and FEDER)*. This collaboration will help TR2Lab to continue developing and deepening research their research into the use of biological therapies and guarantee a better translation of the results to the patient care improvement.

(*) TR2Lab leads FIS PI19/01379 project from the Fondo de Investigación en Salud, and participate of the research fundings that UVic-UCC received for developing the project PECT Osona Transformació Social (PO FEDER of Catalonia 2014-2020, Ref. 001-P-000382).

Sala blanca de l’Hospital Universitàri de la Santa Creu de Vic. Desembre 2019. /Carles Palacio